

Participants were also asked to assess given statements on each tool. The table shows the percentage agreement with essential statements on the TRI of the Accu-Chek Instant glucose monitoring system.

The Accu-Chek Instant Target Range Indicator (TRI) has the potential to lead to **increased knowledge** and consequently **improved glycaemic control** due to appropriate action taken on bG readings.<sup>4</sup>

Statement	% of participants who agreed or somewhat agreed
I believe the TRI support tool will help me to correctly interpret my bG results.	96%
I believe the TRI support tool will help me identify high/low bG values.	96%
I believe the TRI support tool will help me make correct insulin dosage decisions.	80%
I believe the TRI support tool will help me to correctly interpret my bG values.	96%
I believe the graded scale on the TRI is more helpful than a simple “high/low” reading.	96%
I believe I would benefit from using a meter with such a support tool.	94%



Target Range Indicator gives visual reassurance<sup>4</sup>

Helps your patients identify and interpret high and low blood glucose levels correctly<sup>4</sup>

Can be individualised to suit therapy goals

Contact your Roche Diabetes Care representative for more information.

**SIMPLY CLEAR**  
FOR YOUR PATIENTS



1. Diabetes Technology: Standards of Medical Care in Diabetes—2021 American Diabetes Association. Diabetes Care 2021 Jan; 44(Supplement 1): S85-S99.
2. International Diabetes Federation. Global guideline on self-monitoring of blood glucose in non-insulin treated type 2 diabetes. 2009. Available at: <http://www.idf.org/guidelines/self-monitoring>.
3. Cypress M, Tomky D. Using self-monitoring of blood glucose in noninsulin-treated type 2 diabetes. Diabetes Spectr. 2013;26(2):102-106.
4. Parkin CG et al. Use of an integrated tool for interpretation of blood glucose data improves correctness of glycemic risk assessment in individuals with type 1 and type 2 diabetes. J Diabetes Sci Technol. 2017, 11(1), 74-82.




Self-monitoring of blood glucose (SMBG) is recognised by international clinical guidelines as an integral part of diabetes self-management.<sup>1,2</sup> It provides immediate feedback and data that enable people with diabetes to assess the impact of food choices, physical activity levels and medications on their blood glucose control.<sup>1,2</sup>

However, despite the immediate availability of bG information, many patients with diabetes cannot correctly interpret or appropriately act on their SMBG results; this knowledge deficit can adversely affect adherence to testing, and ultimately, clinical outcomes.<sup>1,2,3</sup>

## UNDERSTAND AT A GLANCE

The **Target Range Indicator (TRI)** on the **Accu-Chek Instant blood glucose meter** is an integrated support tool that assists patients in interpreting their blood glucose result. It enables patients to correctly identify bG readings a 9-point scale and a white arrows that show if the test using result is above, within, or below the target range.

The target range is set by default at **70-180 mg/dL\***



Above target range	Dot 9	327 – 600
	Dot 8	254 – 326
	Dot 7	181 – 253
Within target range	Dot 6	144 – 180
	Dot 5	107 – 143
	Dot 4	70 – 106
Below target range	Dot 3	50 – 69
	Dot 2	30 – 49
	Dot 1	10 – 29



High

In-range

Low

*Parkin et al.* recently evaluated the clinical utility and perceived benefits of support tool use by individuals with type 1 and type 2 diabetes<sup>4</sup>.

The study wanted to assess the impact of using data interpretation support tools on participants' ability to correctly interpret bG results, comparing the AC Instant TRI support tool with 2 other on-meter support tools<sup>4</sup>. Data sets from 140 participants were analyzed<sup>4</sup>.

**Participants who used the TRI of the Accu-Chek Instant blood glucose meter achieved significantly better scores than did participants who used either of the other tools<sup>4</sup>.**

\* The AC Instant Target Range Indicator can be personalized to individual therapy goals.